Re: Prostate Trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Prostate Trial

in response to

Prostate Trial

Telepanel

posted on Apr 24, 2020 10:50AM

Telepanel - The trial results you are looking for were News released on Dec 19th 2019. Patients on ZEN-3694 survived an average of 44 weeks longer. That news release is on the Zenith Epigenetics web page under news releases for 2019.